New Once Weekly Investigational Oral Regimen Shows Strong 48 Week Results, Highlighting the Need for Easier HIV Treatment Options
January 20, 2026
A Phase 2 study led by Dr. Joe Eron, chief of the Division of Infectious diseases and a member of the UNC Institute for Global Health and Infectious Diseases (IGHID), shows an investigational once‑weekly, all‑oral combination of islatravir (ISL) and lenacapavir(LEN) maintains high levels of virologic suppression through 48 weeks...